Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Shitara

Showing results (231-240 of 344) with videos related to

Pageof 35
Sort By:
Future Oncology (London, England)|June 11, 2024
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summaryKohei Shitara, Manish A Shah, Florian Lordick, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 8, 2010
Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancerKohei Shitara, Kei Muro, Seiji Ito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2020
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)Shota Fukuoka, Hiroki Hara, Naoki Takahashi, et al.
Annals of Surgical Oncology|November 21, 2018
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 GastrectomyYoshiaki Nakamura, Takeharu Yamanaka, Keisho Chin, et al.
Future Oncology (London, England)|November 10, 2020
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion CohortKohei Shitara, Motohiro Hirao, Satoru Iwasa, et al.
International Journal of Clinical Oncology|August 1, 2025
First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 studyHisateru Yasui, Masaki Aizawa, Kensei Yamaguchi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2024
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidednessTakayuki Yoshino, Naushin Hooda, Diana Younan, et al.
Japanese Journal of Clinical Oncology|December 19, 2022
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062Hironaga Satake, Keun-Wook Lee, Hyun Cheol Chung, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 9, 2016
Dose-escalation study for the targeting of CD44v<sup>+</sup> cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)Kohei Shitara, Toshihiko Doi, Osamu Nagano, et al.
Pageof 35

Showing results (231-240 of 344) with videos related to

Sort By:
Pageof 35
Future Oncology (London, England)|June 11, 2024
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summaryKohei Shitara, Manish A Shah, Florian Lordick, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 8, 2010
Folate intake along with genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase in patients with advanced gastric cancerKohei Shitara, Kei Muro, Seiji Ito, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2020
Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)Shota Fukuoka, Hiroki Hara, Naoki Takahashi, et al.
Annals of Surgical Oncology|November 21, 2018
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 GastrectomyYoshiaki Nakamura, Takeharu Yamanaka, Keisho Chin, et al.
Future Oncology (London, England)|November 10, 2020
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811Hyun Cheol Chung, Yung-Jue Bang, Charles S Fuchs, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Phase I Study of the Liposomal Formulation of Eribulin (E7389-LF): Results from the Advanced Gastric Cancer Expansion CohortKohei Shitara, Motohiro Hirao, Satoru Iwasa, et al.
International Journal of Clinical Oncology|August 1, 2025
First-line pembrolizumab plus chemotherapy for participants in Japan with gastric or gastroesophageal junction adenocarcinoma: subgroup analysis of the phase 3 KEYNOTE-859 studyHisateru Yasui, Masaki Aizawa, Kensei Yamaguchi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 5, 2024
A meta-analysis of efficacy and safety data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in adult patients with RAS wild-type metastatic colorectal cancer by sidednessTakayuki Yoshino, Naushin Hooda, Diana Younan, et al.
Japanese Journal of Clinical Oncology|December 19, 2022
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062Hironaga Satake, Keun-Wook Lee, Hyun Cheol Chung, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|April 9, 2016
Dose-escalation study for the targeting of CD44v<sup>+</sup> cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)Kohei Shitara, Toshihiko Doi, Osamu Nagano, et al.
Pageof 35